Although ischemic stroke is the third most common cause of death in the United States and Europe, the only currently approved medical treatment is the administration of intravenous recombinant tissue plasminogen activator within 4.5 hours of stroke onset (according to the European Stroke Organisation guidelines), with the aim of restoring cerebral blood flow. This evidence concerns the gene PLAT and stroke disorder.